Meet the drug that beat Keytruda

Posted 10 September 2024 AM

MSD's Keytruda is the world's top-selling drug but it could be facing some stiff competition with Summit Therapeutics making history with the release of data showing its lung cancer drug ivonescimab had "decisively" beaten Keytruda in a head-to-head trial.

Phase 3 results were released over the weekend at the World Conference on Lung Cancer in San Diego, revealing the median lung cancer patient treated with ivonescimab went for about 11.1 months before their cancer worsened compared to the median patient on Keytruda who last 5.8 months before disease progression.

To see the whole article, please login